Abstract
1 Intradermal injection of leukotriene B4 (LTB4) or prostaglandin E2 (PGE2), 1 to 100 ng per skin site produced little or no change in plasma exudation in the rabbit, guinea-pig and rat. 2 Intradermal injection of LTB4 or PGE2 together with bradykinin (500 ng) resulted in a significant potentiation of the plasma exudation produced by bradykinin alone in the rabbit and guinea-pig. 4 LTB4 (1 to 10 ng) had no effect on blood flow in the rabbit skin, in contrast to PGE2 which was a potent vasodilator in this species. 5 It is concluded that LTB4 is a mediator of vascular permeability and that this effect can only be observed in the presence of a vasodilator such as PGE2.
Full text
PDF![483](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1452/2071580/08a75180b989/brjpharm00648-0086.png)
![484](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1452/2071580/00a846e51ed5/brjpharm00648-0087.png)
![485](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1452/2071580/a698decda1c9/brjpharm00648-0088.png)
![486](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1452/2071580/15408142c0bb/brjpharm00648-0089.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Borgeat P., Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187. Proc Natl Acad Sci U S A. 1979 May;76(5):2148–2152. doi: 10.1073/pnas.76.5.2148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Borgeat P., Samuelsson B. Metabolism of arachidonic acid in polymorphonuclear leukocytes. Structural analysis of novel hydroxylated compounds. J Biol Chem. 1979 Aug 25;254(16):7865–7869. [PubMed] [Google Scholar]
- Ford-Hutchinson A. W., Walker J. R., Davidson E. M., Smith M. J. PGI2: a potential mediator of inflammation. Prostaglandins. 1978 Aug;16(2):253–258. doi: 10.1016/0090-6980(78)90027-8. [DOI] [PubMed] [Google Scholar]
- Goetzl E. J., Weller P. F., Sun F. F. The regulation of human eosinophil function by endogenous mono-hydroxy-eicosatetraenoic acids (HETEs). J Immunol. 1980 Feb;124(2):926–933. [PubMed] [Google Scholar]
- Morris H. R., Taylor G. W., Piper P. J., Tippins J. R. Slow-reacting substance of anaphylaxis: studies on purification and characterisation. Agents Actions Suppl. 1979;(6):27–36. doi: 10.1007/978-3-0348-7232-4_3. [DOI] [PubMed] [Google Scholar]
- Rådmark O., Malmsten C., Samuelsson B., Clark D. A., Goto G., Marfat A., Corey E. J. Leukotriene A: stereochemistry and enzymatic conversion to leukotriene B. Biochem Biophys Res Commun. 1980 Feb 12;92(3):954–961. doi: 10.1016/0006-291x(80)90795-0. [DOI] [PubMed] [Google Scholar]
- Samuelsson B., Hammarström S. Nomenclature for leukotrienes. Prostaglandins. 1980 May;19(5):645–648. doi: 10.1016/0090-6980(80)90099-4. [DOI] [PubMed] [Google Scholar]
- Williams T. J., Morley J. Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature. 1973 Nov 23;246(5430):215–217. doi: 10.1038/246215a0. [DOI] [PubMed] [Google Scholar]
- Williams T. J., Peck M. J. Role of prostaglandin-mediated vasodilatation in inflammation. Nature. 1977 Dec 8;270(5637):530–532. doi: 10.1038/270530a0. [DOI] [PubMed] [Google Scholar]
- Williams T. J. Prostaglandin E2, prostaglandin I2 and the vascular changes of inflammation. Br J Pharmacol. 1979 Mar;65(3):517–524. doi: 10.1111/j.1476-5381.1979.tb07860.x. [DOI] [PMC free article] [PubMed] [Google Scholar]